The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling. With coverage now centered on the agreed US$36.50 per share cash acquisition by Viatris and the question of any remaining upside to that deal price, this new target range helps anchor how research desks are talking about potential outcomes. As you read on, you will see how to track this evolving narrative and what it could mean for your own view.
Stay updated as the Fair Value for Pacira BioSciences shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Pacira BioSciences.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
RBC Capital lifted its Pacira BioSciences price target from US$25 to US$36.50 once the Viatris cash offer was announced and highlighted what it views as a clean alignment between deal value and fair value.
-
Truist, which previously reinstated Pacira with a Buy rating and a US$30 target, later moved its target to US$36.50 and described the Viatris agreement as having a clean structure with a clear path to closing.
-
JPMorgan upgraded Pacira to Neutral from Underweight with a US$36.50 target, pointing to the transaction and to Viatris infrastructure that could support the planned fast acting meloxicam launch.
🐻 Bearish Takeaways
-
H.C. Wainwright cut Pacira to Neutral from Buy and set a US$36.50 target, citing slower Exparel volume growth and competitive uncertainty, even though the firm viewed the cash premium as positive for existing shareholders.
-
Oppenheimer, Jefferies and Needham each shifted to more neutral stances after the deal was announced, which signals less focus on Pacira BioSciences as a standalone growth story and more on completion of the Viatris tender at the agreed price.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Pacira BioSciences. See which could impact your investment.
How This Changes the Fair Value For Pacira BioSciences
-
Fair value has shifted from US$30.00 to about US$33.57 per share, which is a mid single digit change in the modelled valuation for Pacira BioSciences.
-
Revenue growth moves from about 5.46% to about 5.45% in the updated assumptions.
-
Net profit margin adjusts from about 10.32% to about 8.09% on future revenue.
-
Future P/E is updated from about 13.14x to about 18.75x on projected earnings.
-
The discount rate remains about 7.24% with no change to the risk input.
Never Miss an Update: Follow The Narrative
Narratives connect Pacira BioSciences' business story to a financial forecast and fair value view so you can see what might need to happen for the numbers to line up. They update as new clinical data, policy changes, partnerships and deal news emerge.
Head over to the Simply Wall St Community and follow the Narrative on Pacira BioSciences to stay up to date on:
-
How EXPAREL and ZILRETTA adoption in outpatient and ambulatory surgery settings, supported by separate reimbursement for more than 150 million covered lives, is expected to influence Pacira BioSciences' procedure volumes.
-
The role of the expanded EXPAREL patent estate, partnerships with groups such as Johnson & Johnson MedTech, LG Chem and Zimmer Biomet, and pipeline programs PCRX-201 and PCRX-2002 in broadening Pacira BioSciences' opportunity set.
-
Key risks around Pacira BioSciences' reliance on EXPAREL reimbursement, the scheduled NOPAIN Act expiry after 2027, and the possibility that pipeline spending or clinical results do not translate into new revenue streams.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PCRX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
